NCT07561203 Effect of Collavant® n2 in Healthy Male Adults With Exercise-induced Joint Discomfort.
| NCT ID | NCT07561203 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bioiberica |
| Condition | Healthy Adult Male |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-05-06 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-05-06 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The present clinical study has been designed to evaluate the effect of Collavant® n2 at a daily dose of 40 mg on joint function and performance in healthy, amateur male runners with exercise-induced knee discomfort.
Eligibility Criteria
Inclusion Criteria: * Healthy physically active male adults (amateur runners) with exercise-induced joint discomfort, aged between 40 and 65 years * Activity level: Amateur runners who train regularly a minimum of 150 minutes per week, divided into 2 or more sessions per week during at least 3 months. Principally, subjects training for popular running events of 10 Kms. * Joint discomfort after activity: Self-reports target knee discomfort after training by a score of at least 20 mm VAS at screening. Discomfort persistent for at least 2w. * Be willing to refrain from starting any new dietary supplements during the entire study that have any underlying joint benefits (collagen, glucosamine, chondroitin, MSM, Hyaluronic Acid, Turmeric, Natural Eggshell Membrane, Omega-3 fatty acids, PEA, Boswellia,..). If any of these supplements (except collagen) or any other dietary supplement has been taken consistently for at least 6 months prior to enrollment, participants should maintain the same stable intake pattern throughout the 24 week study period. * Have individual devices to monitor training with GPS * Sign informed consent Exclusion Criteria: * Diagnostic of knee osteoarthritis or any pathology or surgical intervention associated with the knee. * Hypersensitivity to any component of the supplement or the placebo * Chronic treatment with analgesic or anti-inflammatory (NSAIDs and corticosteroids families) drugs * Treatment with any type of collagen supplement * Treatment with probiotics or antibiotics * Inability to train for the next 24 weeks * Follow a vegan diet
Contact & Investigator
Marcela González-Gross, Professor
PRINCIPAL INVESTIGATOR
Universidad Politecnica de Madrid
Frequently Asked Questions
Who can join the NCT07561203 clinical trial?
This trial is open to male participants only, aged 40 Years or older, up to 65 Years, studying Healthy Adult Male. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07561203 currently recruiting?
Yes, NCT07561203 is actively recruiting participants. Contact the research team at monicagarcia@bioiberica.com for enrollment information.
Where is the NCT07561203 trial being conducted?
This trial is being conducted at Madrid, Spain.
Who is sponsoring the NCT07561203 clinical trial?
NCT07561203 is sponsored by Bioiberica. The principal investigator is Marcela González-Gross, Professor at Universidad Politecnica de Madrid. The trial plans to enroll 80 participants.